Artelon® Cosmetic study confirms product application – publication accepted by Clinical Implant Dentistry and Related Research
Västra Frölunda, Sweden, September 28 2010
A post-market study has been conducted by the Brånemark Clinic in Gothenburg on Artelon® Cosmetic for soft tissue augmentation in the upper jaw. The study confirms that patients with tissue defects can be treated successfully with Artelon® Cosmetic.
Dr. Bertil Friberg, who conducted the study at the Brånemark Clinic, states: "Artelon® is an interesting material for dental applications. In this particular study we demonstrate that Artelon® Cosmetic integrates well with body tissue and volume augmentation is maintained over time."
Hans Rosén comments: "The results of the study are very encouraging. Artimplant's operating focus is orthopedics and consequently we have decided not to expand our own sales in the dental area. We are therefore investigating other business alternatives for Artelon® Cosmetic."
For further information, please contact: Hans Rosén, CEO, phone 46 (0)31-746 56 00, 46 (0)708 58 34 70, hans.rosen@artimplant.com
Lars-Johan Cederbrant, CFO, phone 46 (0)31-746 56 54, 46 (0)703 01 68 54, lars-johan.cederbrant@artimplant.com
Further information is available at www.artimplant.com. To subscribe to future press releases please go to www.artimplant.com/investors-media/subscribe-to-press-releases.html
Artimplant
Artimplant’s mission is to restore the health of patients by offering medical professionals degradable implants that help the body to heal. Artimplant is a medical technology company that restores health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products are made from Artelon®, a biomaterial developed by the Company. Artimplant produces implants for the treatment of osteoarthritis and the reinforcement of weakened soft tissue. The Company's products are sold through licensees and own sales under the Artimplant brand take place through agents and distributors. Artimplant is a public company listed on the NASDAQ OMX Stockholm Exchange in the Small Cap segment and in the Healthcare sector.
Forward-looking statements
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.
This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on September 28 2010 at 11:00am (CET).